Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPT155 Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors
NCT04074759Phase 1Terminated
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of FPT155 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Number of Participants Who Experienced Treatment-emergent Adverse Events up to 50 weeks, Number of Participants Who Experienced Dose Limiting Toxicities at 21 days and 1 more. Started Oct 2018; status: terminated.
02
Drugs
FPT155
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04074759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074759.